Skip to main content
. 2024 Jan 7;13(2):337. doi: 10.3390/jcm13020337

Figure 2.

Figure 2

ECV mapping in amyloidosis. CMR-derived ECV map at baseline and after 12 months of Tafamidis treatment in a patient with amyloidosis (52.1 ± 8.2 vs. 49 ± 8.5, %). Tafamidis stabilized cardiac amyloidosis deposition in hereditary transthyretin cardiomiopathy. LV: left ventricular.